Evidence suggests that IRAKs play essential roles in the pathophysiology of cancer and metabolic and inflammatory diseases [39–41]; IRAK1-deficient mice have reduced liver and kidney damage when treated with LPS compared with that of WT mice [42]; IRAK1 deficiency impacts multiple TLR-dependent pathways and decreases early cytokine responses following polymicrobial sepsis [43], highlighting that IRAK1 inhibition has potential therapeutic benefits. This evidence concerns the gene IRAK1 and Sepsis.